Purpose Systemic peripheral T-cell lymphomas (PTCLs) respond poorly to conventional
therapy. To evaluate the efficacy of a dose-dense approach consolidated by up-front high-dose …

Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be
distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used …

Background The survival of patients with diffuse large-B-cell lymphoma after chemotherapy
is influenced by molecular features of the tumors. We used the gene-expression profiles of …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. …

Background Two thirds of patients with advanced Hodgkin's disease are cured with current
approaches to treatment. Prediction of the outcome is important to avoid overtreating some …

Background Patients with follicular lymphoma may survive for periods of less than 1 year to
more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response …

We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma
(MCL), to elucidate its pathogenesis, and to predict the length of survival of these patients…

Background The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma
is crucial because these two types of lymphoma require different treatments. We examined …